FI961666A0 - Genterapi för restenosis vilken använder adenovirusvektor - Google Patents

Genterapi för restenosis vilken använder adenovirusvektor

Info

Publication number
FI961666A0
FI961666A0 FI961666A FI961666A FI961666A0 FI 961666 A0 FI961666 A0 FI 961666A0 FI 961666 A FI961666 A FI 961666A FI 961666 A FI961666 A FI 961666A FI 961666 A0 FI961666 A0 FI 961666A0
Authority
FI
Finland
Prior art keywords
restenosis
gene therapy
adenovirus vector
uses adenovirus
vector
Prior art date
Application number
FI961666A
Other languages
English (en)
Finnish (fi)
Other versions
FI961666A (sv
Inventor
Didier Branellec
Jean-Francois Dedieu
Patrice Denefle
Laurent Feldman
Michel Perricaudet
Gabriel Steg
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI961666A0 publication Critical patent/FI961666A0/sv
Publication of FI961666A publication Critical patent/FI961666A/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01021—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI961666A 1994-08-17 1996-04-16 Genterapi för restenosis vilken använder adenovirusvektor FI961666A (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9410083A FR2723697B1 (fr) 1994-08-17 1994-08-17 Methode de traitement de la restenose par la therapie genique
PCT/FR1995/001074 WO1996005321A1 (fr) 1994-08-17 1995-08-10 Therapie genique de la restenose au moyen de vecteur adenovial

Publications (2)

Publication Number Publication Date
FI961666A0 true FI961666A0 (sv) 1996-04-16
FI961666A FI961666A (sv) 1996-06-06

Family

ID=9466347

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961666A FI961666A (sv) 1994-08-17 1996-04-16 Genterapi för restenosis vilken använder adenovirusvektor

Country Status (12)

Country Link
US (2) US6410011B1 (sv)
EP (1) EP0734448A1 (sv)
JP (1) JPH09504558A (sv)
AU (1) AU3169495A (sv)
CA (1) CA2174232A1 (sv)
FI (1) FI961666A (sv)
FR (1) FR2723697B1 (sv)
IL (1) IL114982A (sv)
MX (1) MX9601368A (sv)
NO (1) NO317720B1 (sv)
WO (1) WO1996005321A1 (sv)
ZA (1) ZA956849B (sv)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
DK0885002T3 (da) * 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
DE19620308A1 (de) * 1996-05-10 1997-11-13 Franz Wolfgang M Dr Vektor-System zur spezifischen in vivo Genexpression in glatten Gefäßmuskelzellen
US7232899B2 (en) * 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
AU6296398A (en) * 1997-02-07 1998-08-26 Leuven Research & Development Vzw Gene therapeutic treatment of blood vessel associated disorders
US6087164A (en) * 1997-10-03 2000-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US7041654B2 (en) 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
ATE344322T1 (de) 1998-02-13 2006-11-15 Koester Hubert Verwendung von ribozymen zur bestimmung der funktion von genen
IL142432A0 (en) 1998-10-05 2002-03-10 Penn State Res Found Compositions and methods for enhancing receptor-mediated cellular internalization
CA2364499C (en) * 1999-03-04 2008-12-23 Introgene B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
AU2001233132A1 (en) 2000-01-31 2001-08-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Hybrid adeno-retroviral vector for the transfection of cells
US20020164333A1 (en) * 2000-07-10 2002-11-07 The Scripps Research Institute Bifunctional molecules and vectors complexed therewith for targeted gene delivery
US7226779B2 (en) * 2001-01-30 2007-06-05 The United States Of America As Represented By The Department Of Health And Human Services Hybrid adenoviral vector
AU2002229823B2 (en) * 2001-04-04 2007-02-15 Delsitech Oy Biodegradable carrier and method for preparation thereof
WO2003083105A1 (fr) * 2002-03-28 2003-10-09 Medicalseed Co., Ltd. Traitement et prevention de l'angiostenose
US20040052161A1 (en) * 2002-09-17 2004-03-18 Steven Liao Mechanical clock having wireless manipulation and adjustment function
WO2011032100A1 (en) 2009-09-11 2011-03-17 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Inhibitors of kshv vil6 and human il6
US11883470B2 (en) 2016-07-25 2024-01-30 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
AU3129993A (en) * 1991-11-08 1993-06-07 Massachusetts Institute Of Technology Localized oligonucleotide therapy
EP0957172B1 (en) * 1992-11-18 2005-10-19 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
WO1994027612A1 (en) * 1993-05-20 1994-12-08 Baylor College Of Medicine Genetic therapy for cardiovascular disease
RU2219241C2 (ru) * 1993-07-13 2003-12-20 Рон-Пуленк Роре С.А. Дефектный рекомбинантный аденовирусный вектор (варианты)
US6682728B1 (en) * 1993-10-13 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Efficient and selective adenoviral-mediated gene transfer into vascular neointima
EP0804249A2 (en) * 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US6780406B1 (en) * 1994-03-21 2004-08-24 The Regents Of The University Of Michigan Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy

Also Published As

Publication number Publication date
CA2174232A1 (fr) 1996-02-22
FI961666A (sv) 1996-06-06
IL114982A0 (en) 1995-12-08
FR2723697A1 (fr) 1996-02-23
NO961504L (no) 1996-04-16
WO1996005321A1 (fr) 1996-02-22
NO961504D0 (no) 1996-04-16
ZA956849B (en) 1996-04-15
AU3169495A (en) 1996-03-07
FR2723697B1 (fr) 1996-09-20
US6410011B1 (en) 2002-06-25
JPH09504558A (ja) 1997-05-06
NO317720B1 (no) 2004-12-02
MX9601368A (es) 1998-06-30
IL114982A (en) 2006-10-31
EP0734448A1 (fr) 1996-10-02
US20020094324A1 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
FI961666A0 (sv) Genterapi för restenosis vilken använder adenovirusvektor
DE69637432D1 (de) Adenovirale vektoren für die gentherapie
ZA963434B (en) Gene therapy using replication competent targeted adenoviral vectors.
EP0710123A4 (en) ADENOVIRUS VECTORS FOR GENE THERAPY
DE69811778D1 (de) Schleifprodukte
DE69728772D1 (de) Verbesserungen mit bezug auf schleifverfahren
FI962114A (sv) Rekombinant adenovirus för genterapi vid kancer
IT1291135B1 (it) Vettori ricombinanti utilizzabili in terapia genica
FI956211A (sv) Skyddsbeläggning för ståldelar
HUP0104046A3 (en) Adenovirus-mediated gene therapy
NO20006047D0 (no) Fremgangsmåte for genterapi
FI954448A (sv) Behandlingssystem för behållare
GB2326097B (en) Apparatus for treating the eyes physically
GB9810991D0 (en) Improved retroviral vectors for gene therapy
DE59812000D1 (de) Bakterielle plasmide
NO993465D0 (no) Adenovirus-vektor-formidlet gen transport inn i modullaere motoriske neuroner
EP1084236A4 (en) NOVEL ADENOVIRAL VECTORS FOR GENE THERAPY
EP1018560A4 (en) CANCER TREATMENT VECTORS
BR9800775B1 (pt) tomada protetora.
FI943989A (sv) Terapeutiska eller preventiva ämnen för peroxilipid anknytande sjukdomar
FI971735A0 (sv) Underifrån uppvärmande bastuaggregat
FI3414U1 (sv) Effektiveringsanordning för bastuugn
FIU970475U0 (sv) Stödarrangemang för börda
SE9701657D0 (sv) Redskap för kroppsvård
IT1290135B1 (it) Pistola erogatrice-dosatrice particolarmente per l'erogazione di pasta abrasiva

Legal Events

Date Code Title Description
FD Application lapsed